4BERGER K, WELTERMANN B, KOLOMINSKY-RA- BAS P, et al. The reliability of stroke scales. The ger- man version of NIHSS, ESS and Rankin scales [ J ]. Fortschr Neurol Psychiatr, 1999, 67 (2) : 81-93.
5ENGLAND T J, BATH P M, SARE G M, et al. Asymp- tomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial[J]. Stroke, 2010, 41 (12): 2834-2839.
6EL-RAYES M, SCHAMPAERT E, HUYNH T, et al. Safety and effectiveness of enoxaparin following fibrinolyt- ic therapy: Results of the Acute Myocardial Infarction (AMI) -QUEBEC registry [ J]. Can J Cardiol, 2010, 26 (8): 431-436.
7JORDAN L C, RAFAY M F, SMITH S E, et al. Interna- tional Pediatric Stroke Study Group. Antithrombotic treat- ment in neonatal cerebral sinovenous thrombosis: results of the International Pediatric Stroke Study[J]. J Pediatr, 2010, 156 (5): 704-710.
8SAXONHOUSE M A, TARQUINIO D, STIEFELHAGEN P, et al. Low-molecular-weight heparin use in a case of noncardiogenic muhifocal perinatal thromboembolic stroke [J]. Adv Hematol, 2009, 151 (25): 17.
9The publication conmmtee for the trial of ORG 10172 in acute treatnlent (TOASTA) investigators. Low molecular weight haparinoid, ORG 10172 ( danaparioid ), and outcome after aeute ischemic stroke. JAMA, 1998,279(16) : 1265 1272.
10Adms HP.Guidelines for the management of patients with acute ischemia.Stroke Circulation,1994,126(9):1588-1592.
